Chronic myeloid leukemia (CML) is a malignant cancer of the blood that affects people of all ages. While treatment is available for most of these patients, approximately 20 percent of them do not respond to it. Researchers at McGill teaching hospitals will soon study the effects of a new alternative therapy.
"Gleevec(TM) has become the standard treatment for CML," says Dr. Carlo Gambacorti-Passerini, Canada Research Chair in Oncology at McGill University. "It is remarkably effective for most patients; however, some become resistant to it. We will be looking at a new drug called BMS-354825.
The new research is planned to start in January at McGill University teaching hospitals, the only institutes in Canada where this treatment will be available. The hospitals that will test BMS-354825 include the Sir Mortimer B. Davis Jewish General Hospital, the McGill University Health Centre and St. Mary's Hospital.
 


New! Sign up for local CML support group meetings in your local community at http://cml.meetup.com

Apply for Commercial Real Estate loans online and submit your deal to dozens of hungry lenders in just minutes. Loan programs for all types of business and commercial real estate. Apply anytime at http://realestatezoo.com

CML (Chronic Myelogenous Leukemia Support List)
---------------------------------
Part Of CMLHope.Com
An International Community Of CML Patients
For more information: http://cmlhope.com

Post Message: [email protected]
Subscribe:  [EMAIL PROTECTED]
Unsubscribe:  [EMAIL PROTECTED]
Change To No Mail/Web: [EMAIL PROTECTED]
Change To Digest: [EMAIL PROTECTED]
Change To Email: [EMAIL PROTECTED]
List Help: [EMAIL PROTECTED] 
CML Group Web Site http://groups.yahoo.com/group/CML




Yahoo! Groups Links

Reply via email to